Mechanistic Insights into Genomic Basis of Crosstalk Between Metabolic Reprogramming and Immune Dysfunction in Ovarian Cancer.
The clinical relevance of metabolic and immune combinations has not yet been demonstrated, while PARP inhibitor-based strategies have already proven relevant in molecularly selected groups of ovarian cancer patients and mechanistic claims discussed in this review are based on preclinical models or on non-ovarian cancer...